Kids' CF drug levels under the microscope: new study aims to personalize dosing
NCT ID NCT07303621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the cystic fibrosis drug combination ETI (elexacaftor-tezacaftor-ivacaftor) behaves in children aged 2 to 17. Researchers will measure drug levels in the blood and see how they relate to the drug's benefits and side effects, such as liver problems or mood changes. The goal is to better understand how to dose the drug safely and effectively in kids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Femme Mère Enfant (HFME)
RECRUITINGBron, 69029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing vs. beating: which technique clears lungs better in cystic fibrosis?
- Could modern CF drugs make daily inhaled treatments obsolete?
- New study investigates hidden heart risks in cystic fibrosis patients on modern drugs
- Blood pressure drug may help preserve insulin in cystic fibrosis
- Hidden toll: depression and anxiety in kids with cystic fibrosis
- Air pollution may worsen cystic fibrosis in kids, study hopes to find out